Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial

Y. Gao; B. Weenink; M. J. van den Bent; L. Erdem-Eraslan; J. M. Kros; P. A. E. Sillevis Smitt; K. Hoang-Xuan; A. A. Brandes; M. Vos; F. Dhermain; R. Enting; G. F. Ryan; O. Chinot; M. Ben Hassel; M. E. van Linde; W. P. Mason; J. M. M. Gijtenbeek; C. Balana; A. von Deimling; Th Gorlia; R. Stupp; M. E. Hegi; B. G. Baumert; P. J. French

doi:10.1016/j.ejca.2018.02.023

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial

Y. Gao, B. Weenink, M. J. van den Bent, L. Erdem-Eraslan, J. M. Kros, P. A. E. Sillevis Smitt, K. Hoang-Xuan, A. A. Brandes, M. Vos, F. Dhermain, R. Enting, G. F. Ryan, O. Chinot, M. Ben Hassel, M. E. van Linde, W. P. Mason, J. M. M. Gijtenbeek, C. Balana, A. von Deimling, Th GorliaR. Stupp, M. E. Hegi, B. G. Baumert, P. J. French

GROW - Innovative Cancer Diagnostics & Therapy

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	168-178
Number of pages	11
Journal	European Journal of Cancer
Volume	94
DOIs	https://doi.org/10.1016/j.ejca.2018.02.023
Publication status	Published - 1 May 2018

Keywords

Low grade glioma
Intrinsic subtype
Pilocytic astrocytoma
Gene expression profiling
Immunophenotype
BELOB
OLIGODENDROGLIAL BRAIN-TUMORS
CENTRAL-NERVOUS-SYSTEM
PHASE-III TRIAL
RANDOMIZED-TRIAL
VINCRISTINE CHEMOTHERAPY
PILOCYTIC ASTROCYTOMAS
ADJUVANT PROCARBAZINE
RADIATION-THERAPY
EORTC 22033-26033
MGMT METHYLATION

Access to Document

10.1016/j.ejca.2018.02.023

Cite this

Gao, Y., Weenink, B., van den Bent, M. J., Erdem-Eraslan, L., Kros, J. M., Smitt, P. A. E. S., Hoang-Xuan, K., Brandes, A. A., Vos, M., Dhermain, F., Enting, R., Ryan, G. F., Chinot, O., Ben Hassel, M., van Linde, M. E., Mason, W. P., Gijtenbeek, J. M. M., Balana, C., von Deimling, A., ... French, P. J. (2018). Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. European Journal of Cancer, 94, 168-178. https://doi.org/10.1016/j.ejca.2018.02.023

Gao, Y. ; Weenink, B. ; van den Bent, M. J. ; Erdem-Eraslan, L. ; Kros, J. M. ; Smitt, P. A. E. Sillevis ; Hoang-Xuan, K. ; Brandes, A. A. ; Vos, M. ; Dhermain, F. ; Enting, R. ; Ryan, G. F. ; Chinot, O. ; Ben Hassel, M. ; van Linde, M. E. ; Mason, W. P. ; Gijtenbeek, J. M. M. ; Balana, C. ; von Deimling, A. ; Gorlia, Th ; Stupp, R. ; Hegi, M. E. ; Baumert, B. G. ; French, P. J. / Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. In: European Journal of Cancer. 2018 ; Vol. 94. pp. 168-178.

@article{24c0b3b261f8469eae7d4f4afce8afec,

title = "Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial",

keywords = "Low grade glioma, Intrinsic subtype, Pilocytic astrocytoma, Gene expression profiling, Immunophenotype, BELOB, OLIGODENDROGLIAL BRAIN-TUMORS, CENTRAL-NERVOUS-SYSTEM, PHASE-III TRIAL, RANDOMIZED-TRIAL, VINCRISTINE CHEMOTHERAPY, PILOCYTIC ASTROCYTOMAS, ADJUVANT PROCARBAZINE, RADIATION-THERAPY, EORTC 22033-26033, MGMT METHYLATION",

author = "Y. Gao and B. Weenink and {van den Bent}, {M. J.} and L. Erdem-Eraslan and Kros, {J. M.} and Smitt, {P. A. E. Sillevis} and K. Hoang-Xuan and Brandes, {A. A.} and M. Vos and F. Dhermain and R. Enting and Ryan, {G. F.} and O. Chinot and {Ben Hassel}, M. and {van Linde}, {M. E.} and Mason, {W. P.} and Gijtenbeek, {J. M. M.} and C. Balana and {von Deimling}, A. and Th Gorlia and R. Stupp and Hegi, {M. E.} and Baumert, {B. G.} and French, {P. J.}",

year = "2018",

month = may,

day = "1",

doi = "10.1016/j.ejca.2018.02.023",

language = "English",

volume = "94",

pages = "168--178",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

}

Gao, Y, Weenink, B, van den Bent, MJ, Erdem-Eraslan, L, Kros, JM, Smitt, PAES, Hoang-Xuan, K, Brandes, AA, Vos, M, Dhermain, F, Enting, R, Ryan, GF, Chinot, O, Ben Hassel, M, van Linde, ME, Mason, WP, Gijtenbeek, JMM, Balana, C, von Deimling, A, Gorlia, T, Stupp, R, Hegi, ME, Baumert, BG & French, PJ 2018, 'Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial', European Journal of Cancer, vol. 94, pp. 168-178. https://doi.org/10.1016/j.ejca.2018.02.023

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. / Gao, Y.; Weenink, B.; van den Bent, M. J.; Erdem-Eraslan, L.; Kros, J. M.; Smitt, P. A. E. Sillevis; Hoang-Xuan, K.; Brandes, A. A.; Vos, M.; Dhermain, F.; Enting, R.; Ryan, G. F.; Chinot, O.; Ben Hassel, M.; van Linde, M. E.; Mason, W. P.; Gijtenbeek, J. M. M.; Balana, C.; von Deimling, A.; Gorlia, Th; Stupp, R.; Hegi, M. E.; Baumert, B. G.; French, P. J.

In: European Journal of Cancer, Vol. 94, 01.05.2018, p. 168-178.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial

AU - Gao, Y.

AU - Weenink, B.

AU - van den Bent, M. J.

AU - Erdem-Eraslan, L.

AU - Kros, J. M.

AU - Smitt, P. A. E. Sillevis

AU - Hoang-Xuan, K.

AU - Brandes, A. A.

AU - Vos, M.

AU - Dhermain, F.

AU - Enting, R.

AU - Ryan, G. F.

AU - Chinot, O.

AU - Ben Hassel, M.

AU - van Linde, M. E.

AU - Mason, W. P.

AU - Gijtenbeek, J. M. M.

AU - Balana, C.

AU - von Deimling, A.

AU - Gorlia, Th

AU - Stupp, R.

AU - Hegi, M. E.

AU - Baumert, B. G.

AU - French, P. J.

PY - 2018/5/1

Y1 - 2018/5/1

KW - Low grade glioma

KW - Intrinsic subtype

KW - Pilocytic astrocytoma

KW - Gene expression profiling

KW - Immunophenotype

KW - BELOB

KW - OLIGODENDROGLIAL BRAIN-TUMORS

KW - CENTRAL-NERVOUS-SYSTEM

KW - PHASE-III TRIAL

KW - RANDOMIZED-TRIAL

KW - VINCRISTINE CHEMOTHERAPY

KW - PILOCYTIC ASTROCYTOMAS

KW - ADJUVANT PROCARBAZINE

KW - RADIATION-THERAPY

KW - EORTC 22033-26033

KW - MGMT METHYLATION

U2 - 10.1016/j.ejca.2018.02.023

DO - 10.1016/j.ejca.2018.02.023

M3 - Article

C2 - 29571083

VL - 94

SP - 168

EP - 178

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -